JP7538040B2 - ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物 - Google Patents

ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物 Download PDF

Info

Publication number
JP7538040B2
JP7538040B2 JP2020538573A JP2020538573A JP7538040B2 JP 7538040 B2 JP7538040 B2 JP 7538040B2 JP 2020538573 A JP2020538573 A JP 2020538573A JP 2020538573 A JP2020538573 A JP 2020538573A JP 7538040 B2 JP7538040 B2 JP 7538040B2
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
alkyl
compound
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020538573A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021510695A (ja
JPWO2019140272A5 (https=
JP2021510695A5 (https=
Inventor
アルバート ジーン ロビチャウド，
フランセスコ ジー． サリトゥロ，
マリア ヘスス ブランコ－ピヤド，
ダニエル ラ，
ボイド エル． ハリソン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sage Therapeutics LLC
Original Assignee
Sage Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics LLC filed Critical Sage Therapeutics LLC
Publication of JP2021510695A publication Critical patent/JP2021510695A/ja
Publication of JPWO2019140272A5 publication Critical patent/JPWO2019140272A5/ja
Publication of JP2021510695A5 publication Critical patent/JP2021510695A5/ja
Priority to JP2023127398A priority Critical patent/JP7817214B2/ja
Application granted granted Critical
Publication of JP7538040B2 publication Critical patent/JP7538040B2/ja
Priority to JP2025061337A priority patent/JP2025106370A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/003—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by oxygen as hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/006—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by sulfur as hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general
    • C07J75/005—Preparation of steroids by cyclization of non-steroid compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2020538573A 2018-01-12 2019-01-11 ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物 Active JP7538040B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023127398A JP7817214B2 (ja) 2018-01-12 2023-08-03 ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物
JP2025061337A JP2025106370A (ja) 2018-01-12 2025-04-02 ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862617134P 2018-01-12 2018-01-12
US201862616768P 2018-01-12 2018-01-12
US62/616,768 2018-01-12
US62/617,134 2018-01-12
US201862728514P 2018-09-07 2018-09-07
US62/728,514 2018-09-07
PCT/US2019/013315 WO2019140272A1 (en) 2018-01-12 2019-01-11 Aza-, oxa and thia-pregnan-20-one-3.alpha.-ol compounds for use in treating cns disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023127398A Division JP7817214B2 (ja) 2018-01-12 2023-08-03 ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物

Publications (4)

Publication Number Publication Date
JP2021510695A JP2021510695A (ja) 2021-04-30
JPWO2019140272A5 JPWO2019140272A5 (https=) 2022-01-18
JP2021510695A5 JP2021510695A5 (https=) 2022-01-18
JP7538040B2 true JP7538040B2 (ja) 2024-08-21

Family

ID=65324563

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020538573A Active JP7538040B2 (ja) 2018-01-12 2019-01-11 ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物
JP2023127398A Active JP7817214B2 (ja) 2018-01-12 2023-08-03 ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物
JP2025061337A Pending JP2025106370A (ja) 2018-01-12 2025-04-02 ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023127398A Active JP7817214B2 (ja) 2018-01-12 2023-08-03 ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物
JP2025061337A Pending JP2025106370A (ja) 2018-01-12 2025-04-02 ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物

Country Status (6)

Country Link
US (3) US11718642B2 (https=)
EP (2) EP4706761A2 (https=)
JP (3) JP7538040B2 (https=)
MA (1) MA51568A (https=)
TW (1) TW201930269A (https=)
WO (1) WO2019140272A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
MX2015002252A (es) 2012-08-21 2015-07-21 Sage Therapeutics Inc Metodos para tratar epilepsia o estado de epilepsia.
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス， インコーポレイテッド １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
TWI904593B (zh) 2016-08-23 2025-11-11 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3720867A1 (en) 2017-12-08 2020-10-14 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
MA51568A (fr) 2018-01-12 2021-04-21 Sage Therapeutics Inc Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
US20230018765A1 (en) * 2019-12-05 2023-01-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
CN111233815B (zh) * 2020-01-21 2022-10-14 上海应用技术大学 一种异阿根廷蚁素的制备方法
KR20220157426A (ko) 2020-03-25 2022-11-29 세이지 테라퓨틱스, 인크. 호흡기 병태의 치료를 위한 작용제의 용도
WO2024118503A1 (en) 2022-11-28 2024-06-06 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016517851A (ja) 2013-04-17 2016-06-20 セージ セラピューティクス， インコーポレイテッド １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL48628A0 (en) * 1974-12-23 1976-02-29 Schering Ag D-homo-20-keto-pregnanes and process for their manufactur
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
AU698834B2 (en) 1993-05-24 1998-11-12 Purdue Pharma Ltd. Methods and compositions for inducing sleep
FI972202L (fi) * 1994-11-23 1997-07-17 Cocensys Inc Androstaanit ja pregnaanit GABA-reseptoreiden allosteeriseen muunteluun
RU2194712C2 (ru) 1995-06-06 2002-12-20 Коукенсис, Инк. НЕЙРОАКТИВНЫЕ СТЕРОИДЫ, ФАРМАЦЕВТИЧЕСКИЙ ПРЕПАРАТ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАЗЛИЧНЫХ НАРУШЕНИЙ, СПОСОБ ИНДУКЦИИ СНА И СПОСОБ ИНДУКЦИИ АНЕСТЕЗИИ С ИХ ИСПОЛЬЗОВАНИЕМ, СПОСОБ МОДУЛИРОВАНИЯ КОМПЛЕКСА РЕЦЕПТОР ГАМКa-ХЛОРИДНЫЙ ИОНОФОР
AU3967297A (en) 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
ME03809B (me) 2014-10-16 2021-04-20 Sage Therapeutics Inc KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a
CN111741965B (zh) 2017-12-22 2024-06-25 萨奇治疗股份有限公司 治疗中枢神经系统疾病的组合物和方法
MA51568A (fr) 2018-01-12 2021-04-21 Sage Therapeutics Inc Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central
CN114656514B (zh) 2018-02-11 2024-05-14 江苏豪森药业集团有限公司 一种甾族类衍生物调节剂及其制备方法和应用
CN109503694A (zh) 2018-11-21 2019-03-22 苏州闻天医药科技有限公司 一种新型gabaa受体调节剂及其用途
IL283629B2 (en) 2018-12-05 2026-03-01 Sage Therapeutics Inc Neuroactive steroids and methods of using them
WO2020135454A1 (zh) 2018-12-26 2020-07-02 张家口华健致远生物科技有限公司 一类类固醇化合物及其用途
TW202143976A (zh) 2020-03-18 2021-12-01 美商賽吉醫療公司 神經活性類固醇及其使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016517851A (ja) 2013-04-17 2016-06-20 セージ セラピューティクス， インコーポレイテッド １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
J. Med. Chem.，2006年，49，3225-3234
Steroids ，2000年，65，349-356
Tetrahedron ，2005年，61，2269-2278
Tetrahedron ，2006年，62，4762-4768
Tetrahedron ，2007年，63，11355-11362

Also Published As

Publication number Publication date
JP7817214B2 (ja) 2026-02-18
JP2023145726A (ja) 2023-10-11
US20260078143A1 (en) 2026-03-19
MA51568A (fr) 2021-04-21
JP2021510695A (ja) 2021-04-30
EP4706761A2 (en) 2026-03-11
TW201930269A (zh) 2019-08-01
EP3737687B1 (en) 2025-10-22
US11718642B2 (en) 2023-08-08
WO2019140272A1 (en) 2019-07-18
US12421275B2 (en) 2025-09-23
US20240150393A1 (en) 2024-05-09
EP3737687A1 (en) 2020-11-18
JP2025106370A (ja) 2025-07-15
US20200354399A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
JP7817214B2 (ja) ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物
JP7670754B2 (ja) Ｃｎｓ障害の処置のための組成物および方法
JP7611186B2 (ja) Ｃ７、ｃ１２、およびｃ１６置換神経刺激性ステロイドおよびそれらの使用方法
JP7720948B2 (ja) 神経刺激性ステロイド及びその使用方法
JP7569412B2 (ja) ＣＮＳ障害を処置するためのジュウテリウム化された２１－［４－シアノ－ピラゾール－１－イル］－１９－ノル－プレガン－３．α－オール－２０－オン誘導体
JP7817179B2 (ja) 神経刺激性ステロイド及びその使用方法
JP7670626B2 (ja) 神経刺激性ステロイド及びその組成物
JP7692830B2 (ja) ３α－ヒドロキシ－１７β－アミド神経刺激性ステロイドおよびその組成物
JP7754725B2 (ja) Ｃｎｓ障害を治療するための組成物及び方法
JP2025078783A (ja) Ｃｎｓ障害の処置のための組成物および方法
JP2024114787A (ja) Ｃ１７、ｃ２０、およびｃ２１置換神経刺激性ステロイドおよびそれらの使用方法
JP7670632B2 (ja) Ｃｎｓ障害を治療するための組成物及び方法
JP7671244B2 (ja) Ｃｎｓ障害の処置において使用するための、１０位において環式基で置換された神経刺激性ステロイド
JP7787635B2 (ja) Ｃｎｓ障害を治療するための組成物及び方法
JP7534291B2 (ja) ９（１１）－不飽和神経刺激性ステロイド及びそれらの使用方法
EA049422B1 (ru) Нейроактивные стероиды и их композиции
TW202608452A (zh) 用於治療cns病症之組合物及方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240401

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240610

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240626

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240808

R150 Certificate of patent or registration of utility model

Ref document number: 7538040

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350